Key facts
- Vetbiolix’s last known valuation is $11.5M.
- It has raised $10.7M; the latest was Later Stage VC ($4.2M) in Dec 2024.
- Notable investors include Bpifrance, Band of Angels, Entropia Capital, Clubster NHL, Eurasanté — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vetbiolix
- ·The full record, as it builds
Funding rounds
No funding rounds for Vetbiolix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vetbiolix
Operator of a veterinary biotechnology company intended to develop products for the treatment and prevention of diseases affecting pets. The company specializes in therapeutic systems and focuses on clinical development of first-in-class drug candidates for pets in periodontitis, osteoarthritis and gut motility disorders, enabling users to provide their pets with effective treatments for common health issues and improve their quality of life.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Loos, France
- Founded
- 2018
- Website
- vetbiolix.com/
- Ownership
- Privately Held (backing)
Vetbiolix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vetbiolix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vetbiolix in its N-PORT filings yet. We sweep new filings monthly.